The potential of inhibiting CTLA-4 for cancer therapy was observed in vivo when administration of anti-CTLA-4 antibodies resulted in rejection of murine colon carcinoma and fibrosarcoma and generation of immunological memory [26]. This evidence concerns the gene CTLA4 and fibrosarcoma.